Cerenome Reports Safe Repeat REYOBIQ Dosing in LM Study
Cerenome reported zero dose-limiting toxicities and consistent delivery across repeat treatments for the first 10 leptomeningeal metastases patients. The early data are encouraging as the company advances dose escalation toward a future randomized study.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed